Cytori Therapeutics, Inc. today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy and its Celution System under the Company's existing and planned regulatory approvals. "Japan's new regenerative medicine laws substantially clarify regulatory ambiguities of pre-existing guidelines and this news represents a significant event for Cytori," said Dr. Marc Hedrick, President & CEO of Cytori.
http://ift.tt/1I44tI2
http://ift.tt/1I44tI2
No comments:
Post a Comment